Mei Ri Jing Ji Xin Wen·2025-09-07 15:30Core Viewpoint - The company Sunflower is planning to acquire controlling stakes in two companies, Zhangzhou Xipu Materials Technology Co., Ltd. and 40% of Zhejiang Beid Pharmaceutical Co., Ltd., through a share issuance and/or cash payment, marking a significant strategic shift into the semiconductor materials sector from its current pharmaceutical focus [1][5]. Group 1: Transaction Details - The transaction is expected to constitute a major asset restructuring as defined by the regulations for listed companies [1][3]. - Sunflower currently holds a 60% stake in Beid Pharmaceutical, and the acquisition of the remaining 40% will make it a wholly-owned subsidiary [3]. - The acquisition of Xipu Materials will involve negotiations with Shanghai Xipu Technology Co., Ltd., which is the main counterparty in this transaction [3][5]. Group 2: Market Context and Performance - Sunflower's recent performance has shown a decline, with a reported revenue of 144 million yuan in the first half of 2025, down 8.33% year-on-year, and a net profit of 1.16 million yuan, down 35.68% [5][6]. - The company has faced challenges in its pharmaceutical business, particularly in the sales of certain products, prompting a strategic pivot to seek external growth opportunities [5][6]. Group 3: Strategic Implications - The acquisition of Xipu Materials represents a significant diversification into the semiconductor materials market, which is distinct from Sunflower's existing pharmaceutical operations [6]. - This move aligns with the company's previously stated strategy of seeking external growth while stabilizing its current business [6].